Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2012-10-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
NCT00293722
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
NCT03531073
A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis, Naïve to Biological Treatment
NCT03828045
Prospective Evaluation of the Radiographic Efficacy of Enbrel
NCT01623752
Identification of New Prognostic Markers in Psoriatic Arthritis
NCT03455166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intensive Care (IC)
Rheumatologists treating to target of DAS28\<2.6
Intensive Care
Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
Routine Care (RC)
Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28\<2.6)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intensive Care
Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must provide written informed consent for participation in the study before any study specific procedures are performed
* Subject has 3 or more SJC on 28 joint count
* Age \>=18
Exclusion Criteria
* Serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient
* If treating with TNF inhibitor, positive PPD \> 5mm who have not received INH for recommended course or untreated TB (ie CXR evidence of latent infection). Usual screening is in place for standard of care.
* Pregnancy, breast-feeding or considering pregnancy over the next 12 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Pope Research Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet E. Pope, MD, MPH, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Pope Research Corp., University of Western Ontario, St. Joseph's Health Care London
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pope Research Corp., 68 Green Acres Drive
London, Ontario, Canada
The Arthritis Program Research Group
Newmarket, Ontario, Canada
Arthur Karasik
Toronto, Ontario, Canada
Institut de Rheumatologie de Montreal
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRC-05-2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.